Taxus Cardium Pharmaceuticals Group (CRXM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -652 | 779 | -553 | -2,097 | -3,014 |
| Depreciation Amortization | 7 | 48 | 54 | 47 | 20 |
| Accounts payable and accrued liabilities | -154 | 769 | -12 | 197 | -118 |
| Other Working Capital | 180 | 719 | 618 | 807 | 452 |
| Other Operating Activity | -514 | -2,452 | -558 | -17 | 636 |
| Operating Cash Flow | $-1,133 | $-137 | $-452 | $-1,062 | $-2,024 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3 | N/A | 650 | N/A | -172 |
| Investing Cash Flow | $-3 | $N/A | $650 | $N/A | $-172 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 194 | 155 | 29 | 212 | N/A |
| Debt Issued | N/A | N/A | -195 | -31 | 104 |
| Other Financing Activity | 1,329 | -100 | 0 | 0 | 3,000 |
| Financing Cash Flow | $1,522 | $55 | $-165 | $181 | $3,104 |
| Beginning Cash Position | 0 | 82 | 49 | 930 | 22 |
| End Cash Position | 386 | 0 | 82 | 49 | 930 |
| Net Cash Flow | $386 | $-82 | $33 | $-881 | $909 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,133 | -137 | -452 | -1,062 | -2,024 |
| Capital Expenditure | -3 | N/A | N/A | N/A | -172 |
| Free Cash Flow | -1,136 | -137 | -452 | -1,062 | -2,195 |